Your browser is no longer supported. Please, upgrade your browser.
Enanta Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.89 Insider Own5.70% Shs Outstand20.09M Perf Week6.33%
Market Cap1.09B Forward P/E- EPS next Y-4.99 Insider Trans-0.49% Shs Float17.86M Perf Month-0.37%
Income-57.90M PEG- EPS next Q-1.24 Inst Own97.00% Short Float11.37% Perf Quarter0.49%
Sales101.60M P/S10.77 EPS this Y-182.00% Inst Trans0.17% Short Ratio14.92 Perf Half Y8.64%
Book/sh22.50 P/B2.29 EPS next Y-49.10% ROA-7.30% Target Price67.86 Perf Year-3.93%
Cash/sh18.21 P/C2.83 EPS next 5Y- ROE-7.70% 52W Range40.32 - 58.59 Perf YTD22.49%
Dividend- P/FCF191.89 EPS past 5Y-19.60% ROI-9.40% 52W High-11.98% Beta0.40
Dividend %- Quick Ratio19.40 Sales past 5Y-5.30% Gross Margin- 52W Low27.90% ATR2.05
Employees141 Current Ratio19.40 Sales Q/Q-39.70% Oper. Margin-40.90% RSI (14)54.12 Volatility4.80% 4.15%
OptionableYes Debt/Eq0.00 EPS Q/Q-164.00% Profit Margin-35.60% Rel Volume0.86 Prev Close50.30
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume136.06K Price51.57
Recom2.50 SMA201.78% SMA502.03% SMA2008.48% Volume116,942 Change2.52%
Jan-29-21Upgrade JP Morgan Underweight → Neutral $55
Nov-24-20Initiated Evercore ISI Underperform $30
Aug-28-20Resumed ROTH Capital Buy $104
Aug-26-20Initiated Piper Sandler Overweight $87
Jul-27-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $70
Mar-17-20Upgrade Robert W. Baird Neutral → Outperform $60
Nov-22-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-26-19Downgrade JP Morgan Neutral → Underweight $86 → $57
May-24-19Initiated Wolfe Research Outperform $117
Apr-23-19Upgrade Berenberg Hold → Buy $80 → $120
Dec-13-18Initiated Berenberg Hold $80
Jun-06-18Initiated ROTH Capital Buy $133
Feb-08-18Downgrade JP Morgan Overweight → Neutral
Jan-02-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-21-17Reiterated RBC Capital Mkts Outperform $54 → $58
Sep-15-17Initiated RBC Capital Mkts Outperform $54
Jul-11-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Apr-28-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated Barclays Underweight $16 → $18
Oct-23-15Upgrade JMP Securities Mkt Perform → Mkt Outperform $32
May-11-21 07:00AM  
May-07-21 09:58AM  
May-06-21 05:45PM  
Apr-29-21 07:00AM  
Apr-28-21 12:33PM  
Mar-02-21 07:01AM  
Feb-18-21 04:02PM  
Feb-08-21 11:00PM  
Feb-05-21 10:09AM  
Feb-01-21 04:02PM  
Jan-28-21 12:32PM  
Jan-26-21 07:00AM  
Jan-08-21 07:01AM  
Jan-05-21 07:01AM  
Dec-19-20 10:40PM  
Dec-08-20 07:01AM  
Nov-25-20 12:10AM  
Nov-23-20 10:00PM  
Nov-20-20 10:03AM  
Nov-18-20 07:02AM  
Nov-16-20 07:02AM  
Nov-12-20 12:30PM  
Oct-27-20 09:54AM  
Oct-12-20 01:27PM  
Sep-28-20 07:00AM  
Sep-14-20 07:00AM  
Sep-03-20 07:01AM  
Aug-28-20 06:15AM  
Aug-26-20 09:42AM  
Aug-20-20 07:00AM  
Aug-07-20 09:28AM  
Aug-05-20 01:31AM  
Aug-04-20 06:35PM  
Aug-03-20 07:02AM  
Jul-28-20 12:32PM  
Jul-17-20 01:41PM  
Jul-09-20 07:01AM  
Jun-29-20 07:00AM  
Jun-23-20 12:23PM  
Jun-11-20 07:02AM  
Jun-04-20 10:20PM  
May-23-20 09:58AM  
May-14-20 08:53AM  
May-12-20 07:30AM  
May-09-20 09:43PM  
May-07-20 12:01AM  
May-06-20 06:45PM  
Apr-29-20 12:34PM  
Apr-28-20 04:05PM  
Apr-17-20 10:19AM  
Mar-26-20 04:05PM  
Mar-13-20 07:00AM  
Mar-06-20 07:05AM  
Mar-04-20 08:09AM  
Feb-12-20 12:18AM  
Feb-06-20 05:15PM  
Feb-05-20 04:11PM  
Feb-03-20 07:27AM  
Jan-30-20 12:31PM  
Jan-24-20 07:30AM  
Jan-14-20 05:30AM  
Jan-09-20 07:30AM  
Jan-04-20 08:44AM  
Dec-30-19 07:30AM  
Dec-11-19 11:25AM  
Dec-09-19 07:38AM  
Dec-07-19 11:24PM  
Nov-22-19 08:18AM  
Nov-21-19 05:15PM  
Nov-17-19 08:42AM  
Nov-14-19 10:30AM  
Nov-11-19 10:21AM  
Nov-05-19 04:00PM  
Oct-27-19 10:29PM  
Oct-21-19 04:00PM  
Oct-12-19 10:03AM  
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Or Yat SunSr. VP & CSOJan 26Option Exercise12.6813,693173,576330,918Jan 28 05:41 PM
MELLETT PAUL JTreasurer and CFOJan 08Sale45.586,000273,46361,759Jan 08 08:57 PM
Gardiner Nathaniel S.Sr. VP & General CounselDec 03Option Exercise30.001,66750,01038,538Dec 07 05:38 PM
MELLETT PAUL JTreasurer and CFONov 11Option Exercise2.543,4808,84946,304Nov 12 04:12 PM
Gardiner Nathaniel S.Sr. VP & General CounselAug 05Option Exercise30.001,66649,98029,271Aug 06 04:38 PM